PIK3CB/p110β is a selective survival factor for glioblastoma

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Glioblastoma (GBM) presents significant therapeutic challenges.
• Phosphoinositide 3-kinase (PI3K) pathway is a potential therapeutic target, but isoform-specific roles in GBM remain unclear.
• Understanding PI3K isoform function is critical for developing effective GBM treatments.

Purpose of the Study:

• To investigate the role of PIK3CB/p110β as a potential biomarker for GBM recurrence.
• To determine the specific contribution of PIK3CB/p110β to GBM cell survival.
• To evaluate PIK3CB/p110β as a selective therapeutic target in GBM.

Main Methods:

• Analysis of PI3K gene expression and clinical data in GBM patients using online databases.
• Assessment of PI3K isoform expression and activity via immunoblotting.
• Inhibition of PI3K isoforms using short hairpin RNAs and selective inhibitors.
• Evaluation of cell viability, growth, and apoptosis using MTS, trypan blue, and caspase activity assays.
• Assessment of therapeutic efficacy in mouse GBM xenograft models.

Main Results:

• PIK3CB/p110β was the sole PI3K isoform significantly correlated with GBM recurrence, incidence, and poor survival.
• PIK3CB/p110β protein levels strongly correlated with PI3K signaling activity in GBM cells.
• Selective inhibition of PIK3CB/p110β effectively suppressed GBM cell viability, growth, and tumor progression in vivo.
• Inhibition of PIK3CB/p110β demonstrated minimal toxicity to normal astrocytes.

Conclusions:

• PIK3CB/p110β serves as a predictive biomarker for GBM recurrence.
• PIK3CB/p110β plays a selective and critical role in GBM cell survival.
• Targeting PIK3CB/p110β represents a promising and selective therapeutic strategy for glioblastoma.